Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00330551 · ClinicalTrials.gov registry record · Phase 4
Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia
A Phase 4 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 4
- Development phase
- 126
- Enrollment target
NCT00330551 is a Phase 4 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 126 participants.
The verdict
NCT00330551, a Phase 4 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 126 participants
- Enrollment target
Study Summary
This study will determine the effectiveness of oral risperidone versus long-acting injectable risperidone in treating people with first-episode schizophrenia.
Interventions
- DRUG Oral Risperidone
- DRUG Risperidone in Long-Acting Injectable Form (Consta)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2006-03 |
| Est. Completion | 2012-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00330551
The ClinicalTrials.gov registry entry for NCT00330551 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Oral Risperidone is the first listed.
NCT00330551 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00330551 about?
NCT00330551 is a clinical study titled "Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia". This study will determine the effectiveness of oral risperidone versus long-acting injectable risperidone in treating people with first-episode schizophrenia.
What is the current status of trial NCT00330551?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 126 participants. The study started on 2006-03. Estimated completion is 2012-11.
What interventions are being tested in trial NCT00330551?
The interventions under investigation include: Oral Risperidone (DRUG), Risperidone in Long-Acting Injectable Form (Consta) (DRUG).
Who is sponsoring clinical trial NCT00330551?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.